3 Results for "

CDK/HDAC-IN-2

" in MedChemExpress (MCE) Product Catalog:
Products (3)

3 Results for "CDK/HDAC-IN-2" in MCE Product Catalog:

  • Targets Recommended:
Cat. No.: HY-146276
CAS No.: 2580938-58-3
Target:  

HDAC CDK Apoptosis

Research Areas:  

Cancer

CDK/HDAC-IN-2 is a potent HDAC/CDK dual inhibitor with IC50 of 6.4, 0.25, 45, >1000, 8.63, 0.30, >1000 nM for HDAC1, HDAC2, HDAC3, HDAC6,8, CDK1, CDK2, CDK4,6,7, respectively. CDK/HDAC-IN-2 shows excellent antiproliferative activities. CDK/HDAC-IN-2 induces apoptosis and cell cycle arrest at G2/M phase. CDK/HDAC-IN-2 shows potent antitumor efficacy .
loading...
    loading...
Cat. No.: HY-143497
CAS No.: 2418559-01-8
Target:  

HDAC CDK Apoptosis

Research Areas:  

Cancer

HDAC1/2 and CDK2-IN-1 (compound 14d) is a potent HDAC1, HDAC2 and CDK2 dual inhibitor, with IC50 values of 70.7, 23.1 and 0.80 μM, respectively. HDAC1/2 and CDK2-IN-1 can block the cell cycle and induce apoptosis. HDAC1/2 and CDK2-IN-1 exhibits desirable in vivo antitumor activity .
loading...
    loading...
Cat. No.: HY-175805
Target:  

EGFR HDAC Apoptosis

Research Areas:  

Cancer

EGFR/HDAC-IN-2 (Compound 38) is dual-functional inhibitor of EGFR and HDAC3 with IC50s of 20.34 and 1.09 nM for CDK9 and HDAC3, respectively. EGFR/HDAC-IN-2 has superior anti-proliferative activity against cancer cells, inhibits cell migration and induces late-stage cell apoptosis. EGFR/HDAC-IN-2 significantly inhibits triple-negative breast cancer (TNBC) tumor growth in xenograft mouse models. EGFR/HDAC-IN-2 can be used for cancers like TNBC research .
loading...
    loading...